PeptiSystems Secures U.S. Patent for Scalable Flow-Through Peptide Manufacturing
PeptiSystems, a life science company pioneering advanced manufacturing solutions for peptide and oligonucleotide drugs, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its flow-through peptide manufacturing technology. The patent protects core elements of the technology, strengthening the company’s position in peptide manufacturing.
Patent protection in the United States strengthens PeptiSystems’ intellectual property position in a key pharmaceutical market and supports its strategy to enable customers to scale efficiently — from process development to commercial production.
The company’s flow-through column technology improves resource efficiency by reducing the consumption of reagents and solvents, resulting in more cost-efficient and sustainable production with a lower environmental footprint. By enabling continuous flow manufacturing, the technology also significantly reduces production times.
“Securing patent protection in the U.S. is a significant milestone for PeptiSystems and strengthens our position in a strategically important market,” says Karin Granath, CEO of PeptiSystems. “We are now advancing into the next phase of our development, with a clear focus on enabling large-scale peptide manufacturing. Demand for peptide-based therapeutics, including GLP-1 analogs, continues to grow rapidly, placing increasing demands on production capacity, cost efficiency, and scalability. Our solution is designed to meet these needs, offering a more cost- and resource-efficient, scalable alternative to conventional manufacturing methods.”
PeptiSystems’ instruments enable automated peptide synthesis with enhanced process control and real-time monitoring compared to traditional batch-based methods. They also facilitate linear scale-up from small-scale development to large-scale production, supporting consistent and predictable performance across scales.
The patent is part of a broader global intellectual property strategy, with corresponding applications filed in several major markets.
For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com
About PeptiSystems AB
PeptiSystems is a life science company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.
Tags:
